Jeff Armitstead

Jeff Armitstead

Auto-generated profile, based on publicly available information

Jeff Armitstead

ResMed Science Center, Sydney, Australia

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
AWAlison Wimms
Alison Wimms
HWHolger Woehrle
Holger Woehrle
SKSahisha Ketheeswaran
Sahisha Ketheeswaran
DRDinesh Ramanan
Dinesh Ramanan
JAJeffery Armitstead
Jeffery Armitstead
Obstructive sleep apnea (OSA) has traditionally been seen as a male disease. However, the importance of OSA in women is increasingly being recognized, along with a number of significant gender-related differences in the symptoms, diagnosis, consequences, and treatment of OSA. Women tend to have less severe OSA than males, with a lower apnea-hypopnea index (AHI) and shorter apneas and hypopneas. Episodes of upper airway resistance that do not meet the criteria for apneas are more common in women. Prevalence rates are lower in women, and proportionally fewer women receive a correct diagnosis. Research has also documented sex differences in the upper airway, fat distribution, and respiratory stability in OSA. Hormones are implicated in some gender-related variations, with differences between men and women in the prevalence of OSA decreasing as age increases. The limited data available suggest that although the prevalence and severity of OSA may be lower in women than in men, the consequences of the disease are at least the same, if not worse for comparable degrees of severity. Few studies have investigated gender differences in the effects of OSA treatment. However, given the differences in physiology and presentation, it is possible that personalized therapy may provide more optimal care.

1 October 2017 in Chest
Verified
Journal Article
Open access
DLDongquan Liu
Dongquan Liu
JAJeff Armitstead
Jeff Armitstead
ABAdam Benjafield
Adam Benjafield
SSShiyun Shao
Shiyun Shao
AMAtul Malhotra
Atul Malhotra
HWHolger Woehrle
Holger Woehrle
The emergence of central sleep apnea (CSA) during positive airway pressure (PAP) therapy has been observed clinically in approximately 10% of obstructive sleep apnea titration studies. This study assessed a PAP database to investigate trajectories of treatment-emergent CSA during continuous PAP (CPAP) therapy. U.S. telemonitoring device data were analyzed for the presence/absence of emergent CSA at baseline (week 1) and week 13. Defined groups were as follows: obstructive sleep apnea (average central apnea index [CAI] < 5/h in week 1, < 5/h in week 13); transient CSA (CAI ≥ 5/h in week 1, < 5/h in week 13); persistent CSA (CAI ≥ 5/h in week 1, ≥ 5/h in week 13); emergent CSA (CAI < 5/h in week 1, ≥ 5/h in week 13). Patients (133,006) used CPAP for ≥ 90 days and had ≥ 1 day with use of ≥ 1 h in week 1 and week 13. The proportion of patients with CSA in week 1 or week 13 was 3.5%; of these, CSA was transient, persistent, or emergent in 55.1%, 25.2%, and 19.7%, respectively. Patients with vs without treatment-emergent CSA were older, had higher residual apnea-hypopnea index and CAI at week 13, and more leaks (all P < .001). Patients with any treatment-emergent CSA were at higher risk of therapy termination vs those who did not develop CSA (all P < .001). Our study identified a variety of CSA trajectories during CPAP therapy, identifying several different clinical phenotypes. Identification of treatment-emergent CSA by telemonitoring could facilitate early intervention to reduce the risk of therapy discontinuation and shift to more efficient ventilator modalities.

15 January 2018 in Journal of Clinical Sleep Medicine
Verified
Journal Article
Closed access
JPJean-Louis Pepin
Jean-Louis Pepin
HWHolger Woehrle
Holger Woehrle
DLDongquan Liu
Dongquan Liu
SSShiyun Shao
Shiyun Shao
JAJeff P. Armitstead
Jeff P. Armitstead
AMAtul Malhotra
Atul Malhotra
There is a lack of data regarding adherence trajectories when switching from continuous positive airway pressure (CPAP) to adaptive servoventilation (ASV) in the context of persistent or treatment-emergent central sleep apnea (CSA). This study investigated 90-day adherence rates in patients with sleep apnea based on the type of positive airway pressure (PAP) device used and any switching of PAP modality over time. Telemonitoring data were obtained from a United States PAP database. Eligible patients were a 30% random sample who started PAP, plus all who started ASV, from January 1, 2015 to October 2, 2015. All received PAP and had at least one session with usage of 1 hour or more. Adherence and device usage were determined in three groups: started on CPAP and stayed on CPAP (CPAP only); started on ASV and stayed on ASV (ASV only); started on CPAP, switched to ASV (Switch). The United States Medicare definition of adherence was used. The study included 198,890 patients; 189,724 (CPAP only), 8,957 (ASV only) and 209 (Switch). In the Switch group, average apnea-hypopnea index decreased significantly on ASV versus CPAP. At 90 days, adherence rates were 73.8% and 73.2% in the CPAP only and ASV only groups. In the Switch group, CPAP adherence was 62.7%, improving to 76.6% after the switch to ASV. Mean device usage at 90 days was 5.27, 5.31, and 5.73 h/d in the CPAP only, ASV only, and Switch groups, respectively. Treatment-emergent or persistent CSA during CPAP reduced therapy adherence, but adherence improved early after switching from CPAP to ASV.

15 July 2022 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
KSKimberly L. Sterling
Kimberly L. Sterling
JPJean-Louis Pepin
Jean-Louis Pepin
WLWalter Linde-Zwirble
Walter Linde-Zwirble
JCJiaming Chen
Jiaming Chen
ABAdam V. Benjafield
Adam V. Benjafield
AMAtul Malhotra
Atul Malhotra
Rationale: The co-occurrence of obstructive sleep apnea and chronic obstructive pulmonary disease, termed overlap syndrome, has a poor prognosis. However, data on positive airway pressure (PAP) treatments and their impact on outcomes and costs are lacking. Objectives: This retrospective observational study investigated the effects of PAP on health outcomes, resource usage, and costs in patients with overlap syndrome. Methods: Deidentified adjudicated claims data for patients with overlap syndrome in the United States were linked to objectively measured PAP user data. Patients were considered adherent to PAP therapy if they met Centers for Medicare and Medicaid Services criteria for eight 90-day timeframes from device setup through 2-year follow-up. Propensity score matching was used to create comparable groups of adherent and nonadherent patients. Healthcare resource usage was based on the number of doctor visits, all-cause emergency room visits, all-cause hospitalizations, and PAP equipment and supplies, and proxy costs were obtained. Measurements and Main Results: A total of 6,810 patients were included (mean age, 60.8 yr; 56% female); 2,328 were nonadherent. Compared with the year before therapy, there were significant reductions in the number of emergency room visits, hospitalizations, and severe acute exacerbations during 2 years of PAP therapy in patients who were versus were not adherent (all P < 0.001). This improvement in health status was paralleled by a significant reduction in the associated healthcare costs. Conclusions: PAP usage by patients with overlap syndrome was associated with reduced all-cause hospitalizations and emergency room visits, severe acute exacerbations, and healthcare costs.

1 April 2009 in SLEEP
Verified
Journal Article
Open access
PDF file
GWGerhard Weinreich
Gerhard Weinreich
JAJeff Armitstead
Jeff Armitstead
VTVolker Töpfer
Volker Töpfer
YWYou-Ming Wang
You-Ming Wang
YWYi Wang
Yi Wang
HTHelmut Teschler
Helmut Teschler
Polysomnography (PSG) is the gold standard in diagnosing sleep disordered breathing (SDB). Diagnostic analysis of SDB is time-consuming and labor-intensive and entails long waiting lists for patients. The aim of this study was to assess the validity of a flow-based screening classifier as an automated diagnostic test for Cheyne-Stokes respiration (CSR). Sleep laboratory 70 study subjects (28 with obstructive sleep apnea [OSA], 20 with CSR, 11 with CSR+OSA and 11 without SDB) The nasal cannula flow signal was analyzed by ApneaLink (ResMed, Sydney, Australia), based on a classifier algorithm using pattern recognition. In a simultaneous PSG, results were compared with manual scoring of respiratory events by certified sleep experts. For detecting CSR we obtained a sensitivity of 87.1% (95% confidence interval 75.3% to 98.9%), a specificity of 94.9% (95% confidence interval 87.9% to 100%), a positive likelihood ratio of 17.0, and a negative likelihood ratio of 0.14. The area under the curve (AUC) of the according receiver operating characteristic (ROC) curve was 93.4%. This resulted in an accuracy of 91.4% for identifying CSR. In this study we demonstrated that the screening classifier was able to detect CSR with high diagnostic accuracy. Hence, ApneaLink equipped with CSR classifier is an appropriate screening tool which may help to prioritize patients with CSR for PSG.

1 November 2015 in SLEEP
Verified
Journal Article
Closed access
NMNigel McArdle
Nigel McArdle
SKStuart King
Stuart King
KSKelly Shepherd
Kelly Shepherd
VBVanessa Baker
Vanessa Baker
DRDinesh Ramanan
Dinesh Ramanan
PEPeter Eastwood
Peter Eastwood
S and full research articles published in SLEEP, the official journal of the APSS. Sleep and sleep disorder scientific findings.